KALA BIO, Inc.
KALA
$2.93
-$0.16-5.18%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.86M | 4.53M | 4.64M | 4.59M | 4.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.23M | 10.66M | 10.88M | 10.65M | 9.46M |
| Operating Income | -10.23M | -10.66M | -10.88M | -10.65M | -9.46M |
| Income Before Tax | 686.00K | -7.56M | -11.16M | -8.95M | -8.18M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 686.00K | -7.56M | -11.16M | -8.95M | -8.18M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 686.00K | -7.56M | -11.16M | -8.95M | -8.18M |
| EBIT | -10.23M | -10.66M | -10.88M | -10.65M | -9.46M |
| EBITDA | -10.17M | -10.53M | -10.81M | -10.58M | -9.39M |
| EPS Basic | 2.70 | -53.70 | -85.64 | -70.49 | -87.07 |
| Normalized Basic EPS | -19.61 | -48.75 | -52.79 | -43.96 | -54.42 |
| EPS Diluted | 2.70 | -53.70 | -85.64 | -70.49 | -87.07 |
| Normalized Diluted EPS | -19.61 | -48.75 | -52.79 | -43.96 | -54.42 |
| Average Basic Shares Outstanding | 253.70K | 140.80K | 130.30K | 126.90K | 93.90K |
| Average Diluted Shares Outstanding | 253.70K | 140.80K | 130.30K | 126.90K | 93.90K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |